RU2000102355A - PHARNESILPROTEINTRANSFERASE INHIBITORS - Google Patents
PHARNESILPROTEINTRANSFERASE INHIBITORSInfo
- Publication number
- RU2000102355A RU2000102355A RU2000102355/04A RU2000102355A RU2000102355A RU 2000102355 A RU2000102355 A RU 2000102355A RU 2000102355/04 A RU2000102355/04 A RU 2000102355/04A RU 2000102355 A RU2000102355 A RU 2000102355A RU 2000102355 A RU2000102355 A RU 2000102355A
- Authority
- RU
- Russia
- Prior art keywords
- tetrahydro
- imidazol
- quinolinyl
- ylmethyl
- methyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 19
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 17
- YIYZHARUXWKUEN-UHFFFAOYSA-N benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1.NS(=O)(=O)C1=CC=CC=C1 YIYZHARUXWKUEN-UHFFFAOYSA-N 0.000 claims 13
- -1 CONR 19 NR 20 Inorganic materials 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000004357 Transferases Human genes 0.000 claims 4
- 108090000992 Transferases Proteins 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 claims 2
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- GCUNUKUKOAVBJK-RJFKIUDMSA-N (3R,5E)-2-(benzenesulfonyl)-3-benzyl-5-(1H-imidazol-5-ylmethylidene)-3,4-dihydro-1H-2-benzazepine-8-carbonitrile Chemical compound C([C@@H]1CC(/C2=CC=C(C=C2CN1S(=O)(=O)C=1C=CC=CC=1)C#N)=C\C=1NC=NC=1)C1=CC=CC=C1 GCUNUKUKOAVBJK-RJFKIUDMSA-N 0.000 claims 1
- GMRODCVDNXSFAA-UHFFFAOYSA-N 1,3-dimethylbenzene Chemical group [CH2]C1=CC=CC(C)=C1 GMRODCVDNXSFAA-UHFFFAOYSA-N 0.000 claims 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 claims 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- DTBHRRDGLARWLZ-UHFFFAOYSA-N 2-Methylbenzyl radical Chemical group [CH2]C1=CC=CC=C1C DTBHRRDGLARWLZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- ISFNHUWQDJRFIT-UHFFFAOYSA-N N-(1H-imidazol-5-ylmethyl)-2-naphthalen-1-ylsulfonyl-8-phenyl-1,3,4,5-tetrahydro-2-benzazepin-5-amine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)N(CC1=CC(=CC=C11)C=2C=CC=CC=2)CCC1NCC1=CNC=N1 ISFNHUWQDJRFIT-UHFFFAOYSA-N 0.000 claims 1
- AYRDIPJIZCLVKE-UHFFFAOYSA-N N-(1H-imidazol-5-ylmethyl)-2-naphthalen-1-ylsulfonylsulfonyl-8-phenyl-1,3,4,5-tetrahydro-2-benzazepin-5-amine Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)S(=O)(=O)N(CC1=CC(=CC=C11)C=2C=CC=CC=2)CCC1NCC1=CN=CN1 AYRDIPJIZCLVKE-UHFFFAOYSA-N 0.000 claims 1
- XNMAVAPAPFLKOC-UHFFFAOYSA-N N-(1H-imidazol-5-ylmethyl)-8-methoxy-2-naphthalen-1-ylsulfonyl-1,3,4,5-tetrahydro-2-benzazepin-5-amine Chemical compound C1CN(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)CC2=CC(OC)=CC=C2C1NCC1=CNC=N1 XNMAVAPAPFLKOC-UHFFFAOYSA-N 0.000 claims 1
- AKFAILRXRKWAAX-UHFFFAOYSA-N N-[4-[3-(azepan-1-yl)propanoyl]phenyl]methanesulfonamide;hydrochloride Chemical compound Cl.C1=CC(NS(=O)(=O)C)=CC=C1C(=O)CCN1CCCCCC1 AKFAILRXRKWAAX-UHFFFAOYSA-N 0.000 claims 1
- NZFVFCGUPFABTM-UHFFFAOYSA-N N-[6-bromo-1-(1H-imidazol-5-ylmethyl)-3,4-dihydro-2H-quinolin-3-yl]benzenesulfonamide Chemical compound C1C(NS(=O)(=O)C=2C=CC=CC=2)CC2=CC(Br)=CC=C2N1CC1=CNC=N1 NZFVFCGUPFABTM-UHFFFAOYSA-N 0.000 claims 1
- RWHPJIGJYDIXEI-UHFFFAOYSA-N N-[6-bromo-1-(1H-imidazol-5-ylmethyl)-3,4-dihydro-2H-quinolin-3-yl]naphthalene-1-carboxamide Chemical compound C1C(NC(=O)C=2C3=CC=CC=C3C=CC=2)CC2=CC(Br)=CC=C2N1CC1=CNC=N1 RWHPJIGJYDIXEI-UHFFFAOYSA-N 0.000 claims 1
- HJRZUHMNPNVXCG-UHFFFAOYSA-N N-[6-bromo-1-(1H-imidazol-5-ylmethyl)-3,4-dihydro-2H-quinolin-3-yl]naphthalene-1-sulfonamide Chemical compound C1C(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)CC2=CC(Br)=CC=C2N1CC1=CNC=N1 HJRZUHMNPNVXCG-UHFFFAOYSA-N 0.000 claims 1
- 229960005137 Succinic Acid Drugs 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- ZSJHIZJESFFXAU-UHFFFAOYSA-N boric acid;phosphoric acid Chemical compound OB(O)O.OP(O)(O)=O ZSJHIZJESFFXAU-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 235000011044 succinic acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
Images
Claims (18)
1, m, r, s и t равны 0 или 1;
n = 0, 1 или 2; Y выбран из группы, состоящей из CHR12, SO2, SO3, CO, CO2, О, NR13, SO2NR14, CONR15, C(NCN), C(NCN)NR16, NR17CO, NR18SO2, CONR19NR20, SO2NR21NR22, S(O)(NR23), S(NR24)(NR25) или Y отсутствует;
Z выбран из группы, состоящей из CR12, S, SO, SO2, SO3, CO, СО2, О, NR13, SO2NR14, CONR15, NR26NR27, ONR28, NR29O, NR30SO2NR31, NR32O2, NR33C(NCN), NR34C(NCN)NR35, NR36CO, NR37CONR38, NR39CO2, OCONR40, S(O)(NR41), S(NR42)(NR43) или CHR12, или Z отсутствует;
R7, R8 выбраны из группы, состоящей из водорода, галоида, нитро, циано и U-R44;
U выбран из группы, состоящей из S, О, NR45, CO, SO, SO2, CO2, NR46CO2, NR47CONR48, NR49SO2, NR50SO2NR51, SO2NR52, NR53CO, CONR54, PO2R55 и РО3Р56 или U отсутствует;
R9, R10, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R41, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58 и R59 выбраны из группы, состоящей из водорода, низшего алкила, арила, гетероцикло, замещенного алкила или арила;
R11 и R44 выбираются из группы, состоящей из водорода, алкила, замещенного алкила, алкенила, замещенного алкенила, алкинила, замещенного алкинила, аралкила, циклоалкила, арила, замещенного арила, гетероцикло, замещенного гетероцикло;
R1, R2, R3, R4, R5 и R6 выбираются из группы, состоящей из водорода, алкила, замещенного алкила, алкенила, замещенного алкенила, алкинила, замещенного алкинила, аралкила, циклоалкила, арила, замещенного арила, гетероцикло, замещенного гетероцикло, циано, алкоксикарбонила, карбокси, замещенного карбамила, отличающегося тем, что заместители при азоте замещенного карбамила выбираются из водорода, алкила, замещенного алкила, арила или аралкила, замещенного арила, гетероцикло, замещенного гетероцикло; любые два заместителя из R1, R2, R3, R4, R5 и R6 могут соединяться с образованием циклоалкильной группы; любые два заместителя из R1, R2, R3, R4, R5 и R6 могут вместе быть оксогруппой, кроме случая, когда атом углерода, у которого есть заместитель, участвует в образовании двойной связи;
R, S и Т выбраны из группы, состоящей из СН2, СО и СH(СН2)pQ, где Q обозначает NR57R58, OR59 или CN;
где р озщначает 0, 1 или 2; и
А, В и С обозначают углерод, кислород, серу или азот; D обозначает углерод, кислород, серу или азот или D отсутствует; его энантиомеры, диастереомеры, фармацевтически приемлемые соли, пролекарства и сольваты;
при условии, что когда 1 и m оба равны 0, n не равен 0;
R11 может обозначать водород, за исключением тех случаев, когда Z обозначает SO или когда Z обозначает О, NR13 или S и атом углерода, к которому он присоединен, участвует в образовании двойной связи или когда Y обозначает SO2, CO2, NR18SO2, S(O)(NR23) или S(NR24)(NR25); и R44 может обозначать водород, кроме случая, когда U обозначает SO, SO2, NR46CO2 или NR49SO2.Where
1, m, r, s, and t are 0 or 1;
n = 0, 1 or 2; Y is selected from the group consisting of CHR 12 , SO 2 , SO 3 , CO, CO 2 , O, NR 13 , SO 2 NR 14 , CONR 15 , C (NCN), C (NCN) NR 16 , NR 17 CO, NR 18 SO 2 , CONR 19 NR 20 , SO 2 NR 21 NR 22 , S (O) (NR 23 ), S (NR 24 ) (NR 25 ) or Y is absent;
Z is selected from the group consisting of CR 12 , S, SO, SO 2 , SO 3 , CO, CO 2 , O, NR 13 , SO 2 NR 14 , CONR 15 , NR 26 NR 27 , ONR 28 , NR 29 O, NR 30 SO 2 NR 31 , NR 32 O 2 , NR 33 C (NCN), NR 34 C (NCN) NR 35 , NR 36 CO, NR 37 CONR 38 , NR 39 CO 2 , OCONR 40 , S (O) ( NR 41 ), S (NR 42 ) (NR 43 ) or CHR 12 , or Z is absent;
R 7 , R 8 are selected from the group consisting of hydrogen, halogen, nitro, cyano, and UR 44 ;
U is selected from the group consisting of S, O, NR 45 , CO, SO, SO 2 , CO 2 , NR 46 CO 2 , NR 47 CONR 48 , NR 49 SO 2 , NR 50 SO 2 NR 51 , SO 2 NR 52 , NR 53 CO, CONR 54 , PO 2 R 55 and PO 3 P 56 or U is absent;
R 9 , R 10 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 41 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 and R 59 are selected from the group consisting of hydrogen, lower alkyl, aryl, heterocyclo, substituted alkyl or aryl;
R 11 and R 44 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo;
R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo , substituted heterocyclo, cyano, alkoxycarbonyl, carboxy, substituted carbamyl, characterized in that the substituents on nitrogen of the substituted carbamyl are selected from hydrogen, alkyl, substituted alkyl, aryl or aralkyl, substituted aryl, heterocyclo, substituted heterocyclo; any two substituents from R 1 , R 2 , R 3 , R 4 , R 5, and R 6 may join to form a cycloalkyl group; any two substituents from R 1 , R 2 , R 3 , R 4 , R 5 and R 6 may together be an oxo group, except for the case when the carbon atom that has a substituent participates in the formation of a double bond;
R, S, and T are selected from the group consisting of CH 2 , CO, and CH (CH 2 ) p Q, where Q is NR 57 R 58 , OR 59, or CN;
where p is 0, 1 or 2; and
A, B and C represent carbon, oxygen, sulfur or nitrogen; D is carbon, oxygen, sulfur or nitrogen or D is absent; its enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs and solvates;
provided that when 1 and m are both equal to 0, n is not equal to 0;
R 11 may denote hydrogen, except when Z is SO or when Z is O, NR 13 or S and the carbon atom to which it is attached participates in the formation of a double bond or when Y denotes SO 2 , CO 2 , NR 18 SO 2 , S (O) (NR 23 ) or S (NR 24 ) (NR 25 ); and R 44 may denote hydrogen, except when U is SO, SO 2 , NR 46 CO 2 or NR 49 SO 2 .
N-[6-бpoм-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -1-нафталинсульфонамид, дигидрохлорид;
N-[6-бpoм-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -1-нафталинкарбоксамид, дигидрохлорид;
N-[6-бpoм-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-(фенилметил)метансульфонамид, дигидрохлорид;
N-[6-бpoм-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -бензолсульфонамид, дигидрохлорид;
N-[6-бpoм-1,2,3,4-тетрагидро-1-(1Н-им идазол-4-илметил )-3-хинолинил] -N-(фенилметил)ацетамид, дигидрохлорид;
N-[6-бpoм-1,2,3,4-тетрагидро-1-(1Н-имид азол-4-илметил)-3-хинолинил] -N-[(4-метоксифенил) метил ] метансульфонамид, моногидрохлорид;
N-[6-бpом-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(4-метилфенил)метил)] метансульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-(хинолинил] -N-[(3-метилфенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(2-метилфенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-(фенилэтил)бензолсульфонамид, моногидрохлорид;
2,3,4,5-тетрагидро-5-[(1Н-имидазол-4-илметил)амино] -2-(1-нафтилсульфонил)-8-метокси-1Н-2-бензазепин, дигидрохлорид;
2,3,4,5-тетрагидро-5-[(1Н-имидазол-4-илметил)амино] -2-(1-нафтилсульфонилсульфонил)-8-фенил-1Н-2-бензазепин, дигидрохлорид;
2,3,4,5-тетрагидро-5-[(1Н-имидазол-4-илметил)амино] -2-(1-нафтилсульфонил)-8-фенил-1Н-2-бензазепин, дигидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(2-этоксифенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-(фенилметил)бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-ил метил)-3-хинолинил] -N-[(2,3-диметоксифенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(3,5-диметилфенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(1-нафталенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(2-тиофен)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(2,5-диметилфенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(3-тиофен)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(3-хлорфенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-[(2-фторфенил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил ] -N-[(3-пиридил)метил)] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-[[1-(метил)-1Н-имидазол-5-ил] метил] -3-хинолинил] -N-(фенилметил)бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-[[1-(метил)-1Н-имидазол-5-ил] метил] -3-хинолинил] -N-[(3-тиофенметил] бензолсульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-(1Н-имидазол-4-илметил)-3-хинолинил] -N-(фенилметил) метансульфонамид, моногидрохлорид;
N-[6-циан-1,2,3,4-тетрагидро-1-[[1-(метил)-1Н-имидазол-5-ил] метил] -3-хинолинил] -N-(фенилметил)метансульфонамид, моногидрохлорид;
(R)-N-[6-циан-1,2,3,4-тетрагидро-1-[[1-(метил )-1Н-имидазол-5-ил] метил] -3-хинолинил] -N-(фенилметил)бензолсульфонамид, моногидрохлорид; и
(R, Е)-8-циан-2,3,4,5-тетрагидро-3-(фенилметил)-2-(фенилсульфонил)-5-[[1Н-имидазол-4-ил] метилен] -1Н-2-бензазепин, моногидрохлорид.8. The compound according to claim 1, which is:
N- [6-bromo-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -1-naphthalenesulfonamide, dihydrochloride;
N- [6-bromo-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -1-naphthalenecarboxamide, dihydrochloride;
N- [6-bromo-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N- (phenylmethyl) methanesulfonamide, dihydrochloride;
N- [6-bromo-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -benzenesulfonamide, dihydrochloride;
N- [6-bromo-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N- (phenylmethyl) acetamide, dihydrochloride;
N- [6-bromo-1,2,3,4-tetrahydro-1- (1H-imide azol-4-ylmethyl) -3-quinolinyl] -N - [(4-methoxyphenyl) methyl] methanesulfonamide, monohydrochloride;
N- [6-BROM-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(4-methylphenyl) methyl)] methanesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (quinolinyl] -N - [(3-methylphenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(2-methylphenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N- (phenylethyl) benzenesulfonamide, monohydrochloride;
2,3,4,5-tetrahydro-5 - [(1H-imidazol-4-ylmethyl) amino] -2- (1-naphthylsulfonyl) -8-methoxy-1H-2-benzazepine, dihydrochloride;
2,3,4,5-tetrahydro-5 - [(1H-imidazol-4-ylmethyl) amino] -2- (1-naphthylsulfonylsulfonyl) -8-phenyl-1H-2-benzazepine, dihydrochloride;
2,3,4,5-tetrahydro-5 - [(1H-imidazol-4-ylmethyl) amino] -2- (1-naphthylsulfonyl) -8-phenyl-1H-2-benzazepine, dihydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(2-ethoxyphenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N- (phenylmethyl) benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-yl methyl) -3-quinolinyl] -N - [(2,3-dimethoxyphenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(3,5-dimethylphenyl) methyl)] benzenesulfonamide, monohydrochloride ;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(1-naphthalenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(2-thiophene) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(2,5-dimethylphenyl) methyl)] benzenesulfonamide, monohydrochloride ;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(3-thiophene) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(3-chlorophenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(2-fluorophenyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N - [(3-pyridyl) methyl)] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1 - [[1- (methyl) -1H-imidazol-5-yl] methyl] -3-quinolinyl] -N- (phenylmethyl) benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1 - [[1- (methyl) -1H-imidazol-5-yl] methyl] -3-quinolinyl] -N - [(3-thiophenmethyl ] benzenesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3-quinolinyl] -N- (phenylmethyl) methanesulfonamide, monohydrochloride;
N- [6-cyano-1,2,3,4-tetrahydro-1 - [[1- (methyl) -1H-imidazol-5-yl] methyl] -3-quinolinyl] -N- (phenylmethyl) methanesulfonamide, monohydrochloride;
(R) -N- [6-cyano-1,2,3,4-tetrahydro-1 - [[1- (methyl) -1H-imidazol-5-yl] methyl] -3-quinolinyl] -N- ( phenylmethyl) benzenesulfonamide, monohydrochloride; and
(R, E) -8-cyan-2,3,4,5-tetrahydro-3- (phenylmethyl) -2- (phenylsulfonyl) -5 - [[1H-imidazol-4-yl] methylene] -1H-2 - benzazepine, monohydrochloride.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5159497P | 1997-07-02 | 1997-07-02 | |
US60/051,594 | 1997-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000102355A true RU2000102355A (en) | 2002-10-27 |
RU2211838C2 RU2211838C2 (en) | 2003-09-10 |
Family
ID=21972255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000102355/04A RU2211838C2 (en) | 1997-07-02 | 1998-06-16 | Derivatives of imidazole, pharmaceutical composition, and methods for inhibition of activity of farnesyl protein transferase and prenyltrans- ferase and suppression of tumor growth |
Country Status (24)
Country | Link |
---|---|
US (2) | US6387926B1 (en) |
EP (1) | EP0994856A4 (en) |
JP (1) | JP2002507989A (en) |
KR (1) | KR100385941B1 (en) |
CN (1) | CN1261880A (en) |
AR (1) | AR016304A1 (en) |
AU (1) | AU734721B2 (en) |
BR (1) | BR9810465A (en) |
CA (1) | CA2294530A1 (en) |
CO (1) | CO4950556A1 (en) |
HU (1) | HUP0004148A3 (en) |
ID (1) | ID24076A (en) |
IL (1) | IL133470A0 (en) |
MY (1) | MY117961A (en) |
NO (1) | NO316117B1 (en) |
NZ (1) | NZ501293A (en) |
PE (1) | PE86599A1 (en) |
PL (1) | PL337697A1 (en) |
RU (1) | RU2211838C2 (en) |
TR (1) | TR199903331T2 (en) |
TW (1) | TW527355B (en) |
UY (1) | UY25074A1 (en) |
WO (1) | WO1999001434A1 (en) |
ZA (1) | ZA985778B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA014756B1 (en) * | 2007-09-11 | 2011-02-28 | Ле Лаборатуар Сервье | Compounds of 1,2,4,5-tetrahydro-3h-benzazepine, a process for the preparation thereof and pharmaceutical compositions containing these compounds |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747023B1 (en) * | 1998-08-11 | 2004-06-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
AU754204B2 (en) * | 1998-09-01 | 2002-11-07 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
US6316436B1 (en) | 1998-12-08 | 2001-11-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU776933B2 (en) * | 1999-12-28 | 2004-09-23 | Eisai R&D Management Co., Ltd. | Heterocyclic compounds having sulfonamide groups |
GB0023915D0 (en) * | 2000-09-29 | 2000-11-15 | Inst Of Ophthalmology | Treatment of neuroinflammatory disease |
WO2002043733A1 (en) * | 2000-11-28 | 2002-06-06 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
FR2819512B1 (en) * | 2001-01-18 | 2003-02-21 | Servier Lab | NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2819510B1 (en) * | 2001-01-18 | 2003-10-31 | Servier Lab | NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2825705B1 (en) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS |
US6740757B2 (en) * | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
FR2835186B1 (en) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
AU2003259717A1 (en) * | 2002-08-07 | 2004-02-25 | Bristol-Myers Squibb Company | Modulators of rabggt and methods of use thereof |
FR2844273B1 (en) | 2002-09-05 | 2008-04-04 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS. |
DK1564210T5 (en) * | 2002-11-20 | 2010-05-03 | Japan Tobacco Inc | 4-Oxoquinoline Compounds and Their Use as HIV Integrase Inhibitors |
EP1644370A4 (en) * | 2003-07-11 | 2008-06-04 | Bristol Myers Squibb Co | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
JP4691041B2 (en) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | GTPase inhibitors and methods of use |
JP2007529555A (en) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | How to treat synucleinopathy |
US20050277629A1 (en) * | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US7531554B2 (en) * | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
WO2006078697A1 (en) | 2005-01-18 | 2006-07-27 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
US7662824B2 (en) | 2005-03-18 | 2010-02-16 | Janssen Pharmaceutica Nv | Acylhydrazones as kinase modulators |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
US8003624B2 (en) * | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
EP2545919A1 (en) * | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Treatment of synucleinopathies |
AU2007223260C1 (en) * | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
US9539303B2 (en) * | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
RU2456281C2 (en) * | 2006-11-16 | 2012-07-20 | Ф. Хоффманн-Ля Рош Аг | Substituted 4-imidazoles, method for preparing and using them |
JP5566282B2 (en) * | 2007-05-10 | 2014-08-06 | アルバニー モレキュラー リサーチ, インコーポレイテッド | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and their use to block norepinephrine, dopamine and serotonin reuptake |
WO2009079765A1 (en) * | 2007-12-21 | 2009-07-02 | Cascade Therapeutics Inc. | Compounds with activity at the 5-ht2c receptor |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
CA2743717A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
WO2013064231A1 (en) | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
US9980942B2 (en) | 2012-05-02 | 2018-05-29 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
CN103864765B (en) * | 2014-03-05 | 2016-02-10 | 天津药物研究院 | Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
EP3452038B1 (en) | 2016-05-05 | 2022-07-06 | Laurus Labs Limited | Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors |
WO2017213210A1 (en) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | Heterocyclic compound |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110536A (en) | 1977-04-18 | 1978-08-29 | Miles Laboratories, Inc. | Derivatives of 5-(indol-3-yl)hydantoin |
JPS5852256A (en) * | 1981-09-24 | 1983-03-28 | Nippon Nohyaku Co Ltd | Substituted or unsubstituted fatty acid amide derivative and its salt |
JPS60222479A (en) * | 1984-04-20 | 1985-11-07 | Nippon Tokushu Noyaku Seizo Kk | Tetrahydroquinolin-1-ylcarbonylimidazole derivative, its intermediate, their production and herbicide and fungicide therefrom |
US4576957A (en) | 1984-07-05 | 1986-03-18 | American Cyanamid Company | N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas |
JPS6160682A (en) * | 1984-08-30 | 1986-03-28 | Nippon Tokushu Noyaku Seizo Kk | Tetrahydroquinolin-1-ylcarbonylimidazole derivative, its intermediate, its production, herbicide, agricultural and horticultural fungicide |
JPS6168487A (en) * | 1984-09-12 | 1986-04-08 | Sumitomo Chem Co Ltd | Carbamoylazole derivative, its production, and herbicide comprising it as active ingredient |
US5017584A (en) | 1984-12-20 | 1991-05-21 | Sterling Drug Inc. | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas |
JPS61227506A (en) * | 1985-04-01 | 1986-10-09 | Nippon Tokushu Noyaku Seizo Kk | Carbamoylimidazole, intermediate and, production thereof and herbicide, agricultural and horticultural fungicide |
JPS61280408A (en) * | 1985-06-03 | 1986-12-11 | Sumitomo Chem Co Ltd | Tobacco sucker inhibitor |
JPS63270678A (en) * | 1987-04-30 | 1988-11-08 | Mitsui Petrochem Ind Ltd | Novel nitrogen-containing compound |
JP2652249B2 (en) | 1989-08-22 | 1997-09-10 | 進 根本 | Key knob cover |
US5374615A (en) | 1990-10-31 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives |
EP0485890A3 (en) * | 1990-11-16 | 1992-07-08 | Hoechst Aktiengesellschaft | Use of 2,3-disubstituate 1-azolyl-propane for inhibiting the pathogenic growth phase of dimorph yeast cell |
US5633376A (en) | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
US5371227A (en) | 1991-10-28 | 1994-12-06 | Synthelabo | Quinoline derivatives, process for their preparation, and their therapeutic applications |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
US5726197A (en) | 1992-11-02 | 1998-03-10 | Syntex (U.S.A.) Inc. | Isoindolinyl derivatives |
US5284841A (en) | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
CA2118985A1 (en) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Heterocyclic inhibitors of farnesyl protein transferase |
US5523317A (en) | 1993-07-05 | 1996-06-04 | Nippon Chemiphar Co., Ltd. | Method of reducing blood pressure |
US5576437A (en) | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
ATE192150T1 (en) | 1993-12-17 | 2000-05-15 | Procter & Gamble | 6-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS AS ALPHA-2-ADRENOCEPTOR ANTAGONISTS |
IL113196A0 (en) * | 1994-03-31 | 1995-06-29 | Bristol Myers Squibb Co | Imidazole derivatives and pharmaceutical compositions containing the same |
US5607939A (en) | 1994-04-28 | 1997-03-04 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
TW436484B (en) | 1996-04-24 | 2001-05-28 | Dev Center Biotechnology | 1,2,3,4-tetrahydroisoquinoline derivatives having a nitrogen-containing heterocyclic methyl substituent, the preparation process and pharmaceutical composition thereof |
AU3460797A (en) | 1996-07-16 | 1998-02-09 | Takeda Chemical Industries Ltd. | Bicyclic compounds for controlling micturition |
UA60311C2 (en) | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Vitronectin receptor antagonists |
-
1998
- 1998-05-26 TW TW087108171A patent/TW527355B/en not_active IP Right Cessation
- 1998-05-29 US US09/087,179 patent/US6387926B1/en not_active Expired - Lifetime
- 1998-06-16 HU HU0004148A patent/HUP0004148A3/en unknown
- 1998-06-16 JP JP50718899A patent/JP2002507989A/en not_active Ceased
- 1998-06-16 TR TR1999/03331T patent/TR199903331T2/en unknown
- 1998-06-16 KR KR10-1999-7012368A patent/KR100385941B1/en not_active IP Right Cessation
- 1998-06-16 RU RU2000102355/04A patent/RU2211838C2/en not_active IP Right Cessation
- 1998-06-16 IL IL13347098A patent/IL133470A0/en unknown
- 1998-06-16 BR BR9810465-9A patent/BR9810465A/en not_active IP Right Cessation
- 1998-06-16 CN CN98806818A patent/CN1261880A/en active Pending
- 1998-06-16 AU AU79719/98A patent/AU734721B2/en not_active Ceased
- 1998-06-16 NZ NZ501293A patent/NZ501293A/en unknown
- 1998-06-16 EP EP98930299A patent/EP0994856A4/en not_active Withdrawn
- 1998-06-16 PL PL98337697A patent/PL337697A1/en unknown
- 1998-06-16 WO PCT/US1998/012549 patent/WO1999001434A1/en not_active Application Discontinuation
- 1998-06-16 CA CA002294530A patent/CA2294530A1/en not_active Abandoned
- 1998-06-26 PE PE1998000565A patent/PE86599A1/en not_active Application Discontinuation
- 1998-06-26 MY MYPI98002919A patent/MY117961A/en unknown
- 1998-06-30 UY UY25074A patent/UY25074A1/en not_active IP Right Cessation
- 1998-07-01 ZA ZA9805778A patent/ZA985778B/en unknown
- 1998-07-01 CO CO98037149A patent/CO4950556A1/en unknown
- 1998-07-02 AR ARP980103223A patent/AR016304A1/en unknown
-
1999
- 1999-06-16 ID IDW991728A patent/ID24076A/en unknown
- 1999-12-30 NO NO19996571A patent/NO316117B1/en unknown
-
2000
- 2000-05-05 US US09/566,396 patent/US6602883B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA014756B1 (en) * | 2007-09-11 | 2011-02-28 | Ле Лаборатуар Сервье | Compounds of 1,2,4,5-tetrahydro-3h-benzazepine, a process for the preparation thereof and pharmaceutical compositions containing these compounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000102355A (en) | PHARNESILPROTEINTRANSFERASE INHIBITORS | |
RU2211838C2 (en) | Derivatives of imidazole, pharmaceutical composition, and methods for inhibition of activity of farnesyl protein transferase and prenyltrans- ferase and suppression of tumor growth | |
US6403581B1 (en) | Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives | |
KR0183374B1 (en) | Compound having vessel smooth muscle relaxation activity | |
KR950032174A (en) | Imidazole-Containing Inhibitor of Panesyl Protein Transferase | |
WO1995014007B1 (en) | Phenyl-alkyl imidazoles as h3-receptor antagonists | |
RU2006137716A (en) | HISTONDEACETYLASE INHIBITORS | |
US20120322877A1 (en) | (bis)urea and (bis)thiorea compounds as eipgenic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
BG65047B1 (en) | Substituted benzimidazoles and their use as parp inhibitors | |
RU2008112683A (en) | FAP INHIBITORS | |
CA2267175A1 (en) | Alpha-9 integrin antagonists and anti-inflammatory compositions thereof | |
JP2009120609A (en) | 2-phenylbenzimidazole and 2-phenylindole, and production and use thereof | |
ATE259365T1 (en) | QUINOLINE DERIVATIVES USABLE FOR INHIBITING FARNESYL-PROTEIN TRANSFERASE | |
RU96107681A (en) | Derivatives of arylsulfonyl hydroxamic acid | |
RU2000105266A (en) | 1- (N-Phenylaminoalkyl) -piperazine derivatives Substituted in Position 2 of the Phenyl Ring | |
NO992960D0 (en) | Substituted nitrogen-containing heterocyclic compounds as inhibitors of p38 protein kinase | |
MXPA04005990A (en) | 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists. | |
TW200503692A (en) | Therapeutic agents | |
Flacke | Alpha2-adrenergic agonists in cardiovascular anesthesia | |
KR880001681A (en) | Novel 1H, 3H-pyrrolo [1,2-C] thiazole derivatives, preparation method thereof and pharmaceutical composition containing them | |
ES2242407T3 (en) | N-ARILAMIDES OF SULFONYLAMINO-CARBOXYL ACIDS IN QUALITY OF ACTIVITIES OF THE CYCLASS GUANILATE. | |
RU2003130752A (en) | ANTIPROSIONAL AGENTS | |
KR20010043529A (en) | Combinations of Protein Farnesyltransferase and HMG CoA Reductase Inhibitors and Their Use to Treat Cancer | |
RU2307829C2 (en) | Carboxamide derivatives | |
DK74988D0 (en) | PREPARED UNTIL Peptide DERIVATIVES, WHICH HAVE A POLYCYCLIC NITROGEN CONTAINING STRUCTURE, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM |